课题基金 / 基金详情

The Use of Incretin-Based Drugs and SGLT-2 Inhibitors for the Prevention of Parkinson's Disease Among Patients with Type 2 Diabetes

The Use of Incretin-Based Drugs and SGLT-2 Inhibitors for the Prevention of Parkinson's Disease Among Patients with Type 2 Diabetes
使用肠促胰岛素药物和 SGLT-2 抑制剂预防 2 型糖尿病患者帕金森病
批准号：
489484
负责人：
Renoux Christel
金额：
$18.39万
依托单位：
Lady Davis Institute for Medical Research (Mtl)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-09-01 至 2026-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=489484&lang=en
关键词：
Cohort Study Electronic Medical Records Incretin-Based Drugs Parkinson'S Disease Pharmacoepidemiology Sglt-2 Inhibitors

项目摘要

项目成果

Renoux Christel的其他基金

相似基金

相关文献

中文摘要
翻译
2型糖尿病（高血糖）患者患帕金森病的风险增加。然而，目前尚不确定血糖控制是否有助于预防糖尿病患者的帕金森病。一些抗糖尿病药物，如i
英文摘要
Patients with type 2 diabetes (high blood sugar) have an increased risk of Parkinson disease development. However, it is uncertain whether blood sugar control can help prevent Parkinson disease in patients with diabetes. Some antidiabetic drugs, such as i
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dihydropyridines for the prevention of dementia among patients with hypertension
Gabapentinoids and the risk of severe respiratory events in patients with chronic obstructive pulmonary disease.
Gabapentinoids and the risk of severe respiratory events in patients with chronic obstructive pulmonary disease
INSPEIR: International Study for the Prevention of Dementia with Incretin-based drugs
海外基金